{"id":2475,"date":"2019-11-07T22:29:48","date_gmt":"2019-11-07T22:29:48","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/~ACP\/?page_id=2475"},"modified":"2019-11-07T22:30:05","modified_gmt":"2019-11-07T22:30:05","slug":"%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc104","status":"publish","type":"page","link":"https:\/\/plaza.umin.ac.jp\/~ACP\/home\/a-homepage-section\/acp-japan-chapter-public-relations-committee-2019%e5%b9%b4%e5%ba%a6%e6%b4%bb%e5%8b%95%e6%96%b9%e9%87%9d\/in-the-clinic-season2-%e6%a5%ad%e5%8b%99%e3%83%95%e3%83%ad%e3%83%bc\/%e8%a4%87%e5%90%88%e8%aa%9e%e5%80%99%e8%a3%9citc104","title":{"rendered":"\u8907\u5408\u8a9e\u5019\u88dcITC104"},"content":{"rendered":"\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
\u8907\u5408\u8a9e<\/th>\u30b9\u30b3\u30a2<\/th>\n<\/tr>\n<\/thead>\n
herpes zoster<\/td>5183.506266798<\/td>\n<\/tr>\n
varicella zoster virus<\/td>844.73314175926<\/td>\n<\/tr>\n
incidence of herpes zoster<\/td>247.94188319859<\/td>\n<\/tr>\n
acute herpes zoster<\/td>207.67493560408<\/td>\n<\/tr>\n
prevention of herpes zoster<\/td>136.02390012756<\/td>\n<\/tr>\n
postherpetic neuralgia<\/td>121.18240878588<\/td>\n<\/tr>\n
antiviral therapy<\/td>115.39564810414<\/td>\n<\/tr>\n
episode of herpes zoster<\/td>111.71086250133<\/td>\n<\/tr>\n
treatment of herpes<\/td>103.76616750019<\/td>\n<\/tr>\n
n engl j med<\/td>96.359922943661<\/td>\n<\/tr>\n
acute pain<\/td>92.919707492375<\/td>\n<\/tr>\n
intravenous acyclovir<\/td>72.376241554004<\/td>\n<\/tr>\n
varicella zoster virus vasculopathy<\/td>69.705940248073<\/td>\n<\/tr>\n
episode of herpes<\/td>67.398102831388<\/td>\n<\/tr>\n
immunocompromised patients<\/td>66.79578440913<\/td>\n<\/tr>\n
pain of herpes zoster<\/td>57.072232811117<\/td>\n<\/tr>\n
live attenuated zoster vaccine<\/td>56.947538877484<\/td>\n<\/tr>\n
herpes zoster vaccine<\/td>55.24745423471<\/td>\n<\/tr>\n
oral acyclovir<\/td>54.99090833947<\/td>\n<\/tr>\n
active herpes zoster<\/td>54.173494431106<\/td>\n<\/tr>\n
herpes zoster ophthalmicus<\/td>51.637323988487<\/td>\n<\/tr>\n
herpes zoster presenting<\/td>51.637323988487<\/td>\n<\/tr>\n
clinical diagnosis of herpes zoster<\/td>51.375113151333<\/td>\n<\/tr>\n
acute episode of herpes zoster<\/td>49.403876373697<\/td>\n<\/tr>\n
varicella vaccine<\/td>46.331687411531<\/td>\n<\/tr>\n
use of herpes<\/td>43.628299137764<\/td>\n<\/tr>\n
severe pain<\/td>42.560804659612<\/td>\n<\/tr>\n
complications of herpes zoster<\/td>42.051180674778<\/td>\n<\/tr>\n
uncomplicated herpes<\/td>41.814001326102<\/td>\n<\/tr>\n
incidence of herpes<\/td>41.684343947313<\/td>\n<\/tr>\n
zoster vaccine<\/td>41.666107508744<\/td>\n<\/tr>\n
history of herpes zoster<\/td>40.984571210074<\/td>\n<\/tr>\n
treatment of herpes zoster<\/td>40.984571210074<\/td>\n<\/tr>\n
varicella zoster virus dna<\/td>40.950757897684<\/td>\n<\/tr>\n
herpes zoster rash<\/td>40.082524921175<\/td>\n<\/tr>\n
immunocompetent patients<\/td>40.079761113877<\/td>\n<\/tr>\n
zoster efficacy study<\/td>39.417088182472<\/td>\n<\/tr>\n
skin lesions<\/td>38.934150409863<\/td>\n<\/tr>\n
severe herpes<\/td>38.791653025852<\/td>\n<\/tr>\n
shingles vaccine<\/td>38.170664872767<\/td>\n<\/tr>\n
immunization practices<\/td>37.951284151613<\/td>\n<\/tr>\n
immunocompetent adults<\/td>35.858543433572<\/td>\n<\/tr>\n
recombinant zoster vaccine<\/td>35.281898729777<\/td>\n<\/tr>\n
had varicella<\/td>35.204469471736<\/td>\n<\/tr>\n
severity of herpes zoster<\/td>34.127162990056<\/td>\n<\/tr>\n
united states<\/td>33.895612242702<\/td>\n<\/tr>\n
severe herpes zoster<\/td>33.762044091568<\/td>\n<\/tr>\n
shingles prevention study group<\/td>33.181441818535<\/td>\n<\/tr>\n
varicella zoster vaccination<\/td>32.846322030069<\/td>\n<\/tr>\n
shingles prevention study<\/td>32.449917580626<\/td>\n<\/tr>\n
disseminated herpes<\/td>32.061953638604<\/td>\n<\/tr>\n
adjuvanted herpes zoster subunit vaccine<\/td>31.77222345061<\/td>\n<\/tr>\n
ann intern med<\/td>31.141969833037<\/td>\n<\/tr>\n
cases of herpes zoster<\/td>31.006585322085<\/td>\n<\/tr>\n
clin infect dis<\/td>30.739889190125<\/td>\n<\/tr>\n
acute retinal necrosis<\/td>30.340013319898<\/td>\n<\/tr>\n
disseminated herpes zoster<\/td>29.734675012037<\/td>\n<\/tr>\n
j infect dis<\/td>29.575246175559<\/td>\n<\/tr>\n
management of herpes zoster<\/td>28.980468226666<\/td>\n<\/tr>\n
subsequent herpes<\/td>27.876000884068<\/td>\n<\/tr>\n
disease control<\/td>26.560366072808<\/td>\n<\/tr>\n
therapy of herpes<\/td>26.465878355799<\/td>\n<\/tr>\n
acute herpes<\/td>26.465878355799<\/td>\n<\/tr>\n
early herpes zoster<\/td>25.818661994244<\/td>\n<\/tr>\n
recurrent herpes zoster<\/td>25.818661994244<\/td>\n<\/tr>\n
herpes zoster of childhood vaccination<\/td>25.481160611561<\/td>\n<\/tr>\n
et al<\/td>25.234737164239<\/td>\n<\/tr>\n
advisory committee<\/td>24.973349415057<\/td>\n<\/tr>\n
varicella zoster infection<\/td>24.756751207287<\/td>\n<\/tr>\n
dose of varicella vaccine<\/td>24.5919113521<\/td>\n<\/tr>\n
developed herpes zoster<\/td>24.131548372928<\/td>\n<\/tr>\n
diagnosing herpes zoster<\/td>24.131548372928<\/td>\n<\/tr>\n
episodes of herpes zoster<\/td>24.131548372928<\/td>\n<\/tr>\n
risk of herpes<\/td>23.971901648529<\/td>\n<\/tr>\n
cutaneous lesions of herpes zoster<\/td>23.837907593557<\/td>\n<\/tr>\n
herpes simplex virus<\/td>23.469378262797<\/td>\n<\/tr>\n
low-dose acyclovir<\/td>23.424041119829<\/td>\n<\/tr>\n
antiviral drugs<\/td>22.925026663968<\/td>\n<\/tr>\n
antiviral treatment<\/td>22.62189070204<\/td>\n<\/tr>\n
dissemination of varicella zoster virus<\/td>22.328559072964<\/td>\n<\/tr>\n
central nervous system<\/td>21.568098473556<\/td>\n<\/tr>\n
varicella zoster virus igg<\/td>21.539883775495<\/td>\n<\/tr>\n
varicella zoster virus transmission<\/td>21.539883775495<\/td>\n<\/tr>\n
transmission of varicella zoster virus<\/td>21.539883775495<\/td>\n<\/tr>\n
efficacy of zoster vaccine<\/td>20.943453264666<\/td>\n<\/tr>\n
possible varicella zoster<\/td>20.91565822694<\/td>\n<\/tr>\n
cutaneous healing of herpes zoster<\/td>20.435204196548<\/td>\n<\/tr>\n
harpaz r<\/td>19.817003712138<\/td>\n<\/tr>\n
varicella zoster virus retinitis<\/td>18.776005282236<\/td>\n<\/tr>\n
possibility of varicella zoster virus<\/td>18.776005282236<\/td>\n<\/tr>\n
zosteriform herpes simplex<\/td>18.751775539312<\/td>\n<\/tr>\n
family history of herpes zoster<\/td>18.58255614553<\/td>\n<\/tr>\n
oral antiviral therapy<\/td>18.558378711077<\/td>\n<\/tr>\n
varicella vaccination program<\/td>18.367718043369<\/td>\n<\/tr>\n
neuralgic pain<\/td>18.350726547188<\/td>\n<\/tr>\n
live attenuated varicella zoster virus vaccine<\/td>18.111232638103<\/td>\n<\/tr>\n
multifocal vasculopathy<\/td>17.773539825992<\/td>\n<\/tr>\n
live zoster vaccine<\/td>17.640949364888<\/td>\n<\/tr>\n
oral acyclovir therapy<\/td>16.922206158072<\/td>\n<\/tr>\n
cutaneous healing<\/td>16.757054048864<\/td>\n<\/tr>\n
percent of patients<\/td>16.647165801151<\/td>\n<\/tr>\n
history of zoster rash<\/td>16.622829872088<\/td>\n<\/tr>\n
disseminated zoster<\/td>16.451644568508<\/td>\n<\/tr>\n
influenza vaccine<\/td>16.214401857684<\/td>\n<\/tr>\n
zoster vaccine introduction<\/td>16.201199197581<\/td>\n<\/tr>\n
complication rates of herpes zoster<\/td>16.198145541661<\/td>\n<\/tr>\n
population-based study<\/td>15.954887690835<\/td>\n<\/tr>\n
vaccine group<\/td>15.937130414921<\/td>\n<\/tr>\n
oral treatment of herpes<\/td>15.92383273608<\/td>\n<\/tr>\n
differential diagnosis of herpes zoster<\/td>15.833161478903<\/td>\n<\/tr>\n
immune system<\/td>15.79288815543<\/td>\n<\/tr>\n
herpes simplex virus infection<\/td>15.692026165119<\/td>\n<\/tr>\n
duration of herpes<\/td>15.424933085974<\/td>\n<\/tr>\n
hours of lesion onset<\/td>15.139721272633<\/td>\n<\/tr>\n
history of varicella<\/td>14.801656089846<\/td>\n<\/tr>\n
chickenpox virus<\/td>14.742090873255<\/td>\n<\/tr>\n
ocular involvement<\/td>14.325905783504<\/td>\n<\/tr>\n
trigeminal zoster<\/td>14.303746543502<\/td>\n<\/tr>\n
ischemic lesions<\/td>14.042083915924<\/td>\n<\/tr>\n
introduction of zoster vaccination<\/td>14.001630789771<\/td>\n<\/tr>\n
safety of herpes<\/td>13.938000442034<\/td>\n<\/tr>\n
ocular complications<\/td>13.759162513002<\/td>\n<\/tr>\n
dermatomal zoster<\/td>13.311136036748<\/td>\n<\/tr>\n
localized zoster<\/td>13.311136036748<\/td>\n<\/tr>\n
live attenuated herpes<\/td>13.197398237193<\/td>\n<\/tr>\n
collaborative famciclovir herpes zoster study group<\/td>12.637151777336<\/td>\n<\/tr>\n
reactivation of varicella zoster virus increases<\/td>12.493890175145<\/td>\n<\/tr>\n
lass j<\/td>12.183259109214<\/td>\n<\/tr>\n
serious adverse events<\/td>11.912482232343<\/td>\n<\/tr>\n
schmader ke<\/td>11.771323825531<\/td>\n<\/tr>\n
tolerability of herpes<\/td>11.720414607511<\/td>\n<\/tr>\n
ocular inflammatory complications of herpes<\/td>11.644979764212<\/td>\n<\/tr>\n
new recombinant zoster vaccine<\/td>11.47866721188<\/td>\n<\/tr>\n
cutaneous lesions<\/td>11.401079531087<\/td>\n<\/tr>\n
mild pain<\/td>11.384850195244<\/td>\n<\/tr>\n
chronic pain<\/td>11.384850195244<\/td>\n<\/tr>\n
attenuated zoster vaccination coverage<\/td>11.380099575338<\/td>\n<\/tr>\n
live virus vaccine<\/td>11.339001382966<\/td>\n<\/tr>\n
neurologic complications<\/td>11.269252989045<\/td>\n<\/tr>\n
levin mj<\/td>11.132630734855<\/td>\n<\/tr>\n
childhood varicella<\/td>11.066819197003<\/td>\n<\/tr>\n
involved skin<\/td>11.059433928161<\/td>\n<\/tr>\n
childhood varicella vaccination<\/td>11.029235690267<\/td>\n<\/tr>\n
risk factors<\/td>10.911407287692<\/td>\n<\/tr>\n
years of age<\/td>10.63659179389<\/td>\n<\/tr>\n
wood mj<\/td>10.63659179389<\/td>\n<\/tr>\n
pain control<\/td>10.594796911844<\/td>\n<\/tr>\n
serologic testing<\/td>10.583005244258<\/td>\n<\/tr>\n
severe cases of herpes<\/td>10.411483427417<\/td>\n<\/tr>\n
acyclovir therapy<\/td>10.047658220351<\/td>\n<\/tr>\n
vaccination program<\/td>9.8984640076795<\/td>\n<\/tr>\n
previous zoster infection<\/td>9.8636347990426<\/td>\n<\/tr>\n
natural history of herpes<\/td>9.8363850920969<\/td>\n<\/tr>\n
central nervous system involvement<\/td>9.7518455544798<\/td>\n<\/tr>\n
potential severity of shingles<\/td>9.7110004981407<\/td>\n<\/tr>\n
typical symptoms of herpes<\/td>9.5419832218598<\/td>\n<\/tr>\n
health care<\/td>9.4762744410752<\/td>\n<\/tr>\n
everyday activities<\/td>8.9442719099992<\/td>\n<\/tr>\n
clinical practice<\/td>8.8534553576026<\/td>\n<\/tr>\n
late complication of herpes<\/td>8.7632228696839<\/td>\n<\/tr>\n
acyclovir halts progression of herpes<\/td>8.587954697497<\/td>\n<\/tr>\n
contralateral hemiparesis<\/td>8.4852813742386<\/td>\n<\/tr>\n
long-term persistence of zoster vaccine efficacy<\/td>8.2824004707631<\/td>\n<\/tr>\n
immunocompromised persons<\/td>8.2390685756285<\/td>\n<\/tr>\n
virus transmission<\/td>8.157402714005<\/td>\n<\/tr>\n
double-blind rct<\/td>8.1324180324886<\/td>\n<\/tr>\n
severe acute pain<\/td>8.0542871296697<\/td>\n<\/tr>\n
common indicator of herpes<\/td>8.0103222774806<\/td>\n<\/tr>\n
recombinant shingles vaccine<\/td>7.999674446048<\/td>\n<\/tr>\n
recurrent herpes simplex infection<\/td>7.8851895052982<\/td>\n<\/tr>\n
one rct<\/td>7.770060192334<\/td>\n<\/tr>\n
placebo-controlled trial<\/td>7.7025702136862<\/td>\n<\/tr>\n
subunit vaccine<\/td>7.6673172509553<\/td>\n<\/tr>\n
antiviral agents<\/td>7.6416755546559<\/td>\n<\/tr>\n
normal renal function<\/td>7.5595262993692<\/td>\n<\/tr>\n
visceral dissemination<\/td>7.5446005780976<\/td>\n<\/tr>\n
median follow-up<\/td>7.5446005780976<\/td>\n<\/tr>\n
systemic antiviral therapy<\/td>7.4953678880267<\/td>\n<\/tr>\n
immune status<\/td>7.4448388728168<\/td>\n<\/tr>\n
immunocompetent persons<\/td>7.4155855021347<\/td>\n<\/tr>\n
am j med<\/td>7.3446842811871<\/td>\n<\/tr>\n
live vaccine<\/td>7.3256830029694<\/td>\n<\/tr>\n
acute disease<\/td>7.2794618755762<\/td>\n<\/tr>\n
increased risk<\/td>7.2742715251283<\/td>\n<\/tr>\n
intravenous acyclovir therapy<\/td>7.2287728000983<\/td>\n<\/tr>\n
gilden d. neurological complications of varicella zoster virus reactivation<\/td>7.226859299044<\/td>\n<\/tr>\n
safety profile of varicella vaccine<\/td>7.1606173454213<\/td>\n<\/tr>\n
n z med j<\/td>7.1599738063165<\/td>\n<\/tr>\n
adverse ocular complications<\/td>7.0752101004428<\/td>\n<\/tr>\n
new lesion formation<\/td>7.0752101004428<\/td>\n<\/tr>\n
topical antiviral therapy<\/td>7.0627845845626<\/td>\n<\/tr>\n
oral analgesics<\/td>6.9282032302755<\/td>\n<\/tr>\n
johnson gr<\/td>6.9009799013736<\/td>\n<\/tr>\n
antiviral drug therapy<\/td>6.8836401999298<\/td>\n<\/tr>\n
virus replication<\/td>6.8595306999877<\/td>\n<\/tr>\n
duration of pain<\/td>6.7694724277124<\/td>\n<\/tr>\n
anti?varicella zoster virus igg antibody<\/td>6.711207761057<\/td>\n<\/tr>\n
bandlike rash<\/td>6.700737917669<\/td>\n<\/tr>\n
history of rash<\/td>6.700737917669<\/td>\n<\/tr>\n
imaging studies<\/td>6.700737917669<\/td>\n<\/tr>\n
varicella conflicts<\/td>6.6874030497642<\/td>\n<\/tr>\n
varicella seroprevalence<\/td>6.6874030497642<\/td>\n<\/tr>\n
varicella vaccinees<\/td>6.6874030497642<\/td>\n<\/tr>\n
other antiviral agents<\/td>6.4942575804746<\/td>\n<\/tr>\n
infectious disease specialist<\/td>6.4062018950577<\/td>\n<\/tr>\n
randomized trial of acyclovir<\/td>6.4042231448869<\/td>\n<\/tr>\n
pain control measures<\/td>6.3079768610042<\/td>\n<\/tr>\n
disseminated skin lesions<\/td>6.3051701955963<\/td>\n<\/tr>\n
trigeminal nerve<\/td>6.2603383202932<\/td>\n<\/tr>\n
clinical trials<\/td>6.2603383202932<\/td>\n<\/tr>\n
skin diseases<\/td>6.2191767310173<\/td>\n<\/tr>\n
lesions of patients<\/td>6.160140576482<\/td>\n<\/tr>\n
treatment of patients<\/td>6.160140576482<\/td>\n<\/tr>\n
concomitant antiviral therapy<\/td>6.1326262302568<\/td>\n<\/tr>\n
optimal antiviral therapy<\/td>6.1326262302568<\/td>\n<\/tr>\n
pain specialist<\/td>6.1169088490625<\/td>\n<\/tr>\n
sutphin j<\/td>6.0916295546068<\/td>\n<\/tr>\n
topical acyclovir<\/td>6.0860922072299<\/td>\n<\/tr>\n
antiviral medications<\/td>6.0772008873526<\/td>\n<\/tr>\n
pediatr infect dis j<\/td>6.0671409520631<\/td>\n<\/tr>\n
health history<\/td>6.0548002080702<\/td>\n<\/tr>\n
medicare part d<\/td>6.0523429976916<\/td>\n<\/tr>\n
skin changes<\/td>6.014990027444<\/td>\n<\/tr>\n
oxman mn<\/td>6<\/td>\n<\/tr>\n
cochrane database syst rev<\/td>5.9906903399616<\/td>\n<\/tr>\n
other complications<\/td>5.9245132753306<\/td>\n<\/tr>\n
low-dose oral acyclovir<\/td>5.9036187547454<\/td>\n<\/tr>\n
introduction of varicella vaccination programs<\/td>5.8856619127654<\/td>\n<\/tr>\n
severe allergy<\/td>5.8856619127654<\/td>\n<\/tr>\n
chickenpox vaccine<\/td>5.8259012604879<\/td>\n<\/tr>\n
skin biopsy<\/td>5.7875960854994<\/td>\n<\/tr>\n
2-shot varicella vaccine series<\/td>5.7237619056446<\/td>\n<\/tr>\n
antiviral drugs famciclovir<\/td>5.6945454450228<\/td>\n<\/tr>\n
physical examination<\/td>5.5663153674275<\/td>\n<\/tr>\n
retinal necrosis<\/td>5.5663153674275<\/td>\n<\/tr>\n
domingo j<\/td>5.5044086707916<\/td>\n<\/tr>\n
fingeroth j<\/td>5.5044086707916<\/td>\n<\/tr>\n
taylor j<\/td>5.5044086707916<\/td>\n<\/tr>\n
storek j<\/td>5.5044086707916<\/td>\n<\/tr>\n
marley j<\/td>5.5044086707916<\/td>\n<\/tr>\n
yang j<\/td>5.5044086707916<\/td>\n<\/tr>\n
crooks j<\/td>5.5044086707916<\/td>\n<\/tr>\n
listing j<\/td>5.5044086707916<\/td>\n<\/tr>\n
diez-domingo j<\/td>5.5044086707916<\/td>\n<\/tr>\n
decroix j<\/td>5.5044086707916<\/td>\n<\/tr>\n
pennella-vaughan j<\/td>5.5044086707916<\/td>\n<\/tr>\n
placebo group<\/td>5.4711295994695<\/td>\n<\/tr>\n
double-blind clinical trial<\/td>5.4197492421882<\/td>\n<\/tr>\n
around-the-clock pain control<\/td>5.4146047111091<\/td>\n<\/tr>\n
j clin virol<\/td>5.399676491374<\/td>\n<\/tr>\n
zhou m<\/td>5.3706992285653<\/td>\n<\/tr>\n
chlibek r<\/td>5.3446902355676<\/td>\n<\/tr>\n
mmwr morb mortal wkly rep<\/td>5.3345372167932<\/td>\n<\/tr>\n
other antiviral treatments<\/td>5.3135289660276<\/td>\n<\/tr>\n
confirmatory laboratory testing<\/td>5.2733493302731<\/td>\n<\/tr>\n
systematic review<\/td>5.26429605181<\/td>\n<\/tr>\n
severe ear pain<\/td>5.252546217199<\/td>\n<\/tr>\n
10.8 percent of vaccine recipients<\/td>5.2169309429792<\/td>\n<\/tr>\n
cunningham al<\/td>5.1510191538028<\/td>\n<\/tr>\n
pain resolution<\/td>5.1436867236104<\/td>\n<\/tr>\n
cessation of pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
unrelenting pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
pain relief<\/td>5.1436867236104<\/td>\n<\/tr>\n
zoster?associated pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
prodromal pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
persistent pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
protracted pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
prolonged pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
zoster-associated pain<\/td>5.1436867236104<\/td>\n<\/tr>\n
controlled clinical trials<\/td>5.1395931737013<\/td>\n<\/tr>\n
development of skin lesions<\/td>5.1170399378161<\/td>\n<\/tr>\n
antiviral prophylaxis<\/td>5.1102964409515<\/td>\n<\/tr>\n
rash severity<\/td>5.0914597900437<\/td>\n<\/tr>\n
other serious complications<\/td>5.0830352786163<\/td>\n<\/tr>\n
studies of patients<\/td>5.0099701392346<\/td>\n<\/tr>\n
infectious diseases collaborative antiviral study group<\/td>4.9736700491369<\/td>\n<\/tr>\n
rash healing<\/td>4.9242980521049<\/td>\n<\/tr>\n
vaccine component<\/td>4.8989794855664<\/td>\n<\/tr>\n
family history of shingles<\/td>4.8555002490703<\/td>\n<\/tr>\n
had shingles<\/td>4.8339055525626<\/td>\n<\/tr>\n
clinical trials of rzv<\/td>4.803747820704<\/td>\n<\/tr>\n
pharmacokinetic characteristics<\/td>4.7568284600109<\/td>\n<\/tr>\n
contact dermatitis<\/td>4.7568284600109<\/td>\n<\/tr>\n
onset of rash<\/td>4.7381372205376<\/td>\n<\/tr>\n
bacterial superinfection<\/td>4.6806946386414<\/td>\n<\/tr>\n
patient information<\/td>4.6806946386414<\/td>\n<\/tr>\n
viral culture<\/td>4.6806946386414<\/td>\n<\/tr>\n
lack of awareness<\/td>4.6806946386414<\/td>\n<\/tr>\n
j cutan med surg<\/td>4.6248450950756<\/td>\n<\/tr>\n
other symptoms<\/td>4.5799756509618<\/td>\n<\/tr>\n
wilhelmus k<\/td>4.5590141139096<\/td>\n<\/tr>\n
larussa p<\/td>4.5590141139096<\/td>\n<\/tr>\n
kawai k<\/td>4.5590141139096<\/td>\n<\/tr>\n
injection site<\/td>4.5590141139096<\/td>\n<\/tr>\n
seasonal influenza vaccine<\/td>4.5298688016454<\/td>\n<\/tr>\n
inactivated influenza vaccine<\/td>4.5298688016454<\/td>\n<\/tr>\n
pine study<\/td>4.4721359549996<\/td>\n<\/tr>\n
combined acyclovir<\/td>4.4496055862541<\/td>\n<\/tr>\n
acyclovir fs<\/td>4.4496055862541<\/td>\n<\/tr>\n
clinical appearance<\/td>4.4267276788013<\/td>\n<\/tr>\n
late ocular inflammatory complications<\/td>4.4111669921668<\/td>\n<\/tr>\n
limited skin involvement<\/td>4.4036997674034<\/td>\n<\/tr>\n
skin disorders<\/td>4.3976220398999<\/td>\n<\/tr>\n
skin inflammation<\/td>4.3976220398999<\/td>\n<\/tr>\n
uninvolved skin<\/td>4.3976220398999<\/td>\n<\/tr>\n
balfour hh jr<\/td>4.3644945438869<\/td>\n<\/tr>\n
neurologic symptoms<\/td>4.3558771746929<\/td>\n<\/tr>\n
oral valacyclovir<\/td>4.3558771746929<\/td>\n<\/tr>\n
randomized trial<\/td>4.331473541336<\/td>\n<\/tr>\n
early pain management<\/td>4.2975746072033<\/td>\n<\/tr>\n
hwang sj<\/td>4.2813902858562<\/td>\n<\/tr>\n
liesegang t<\/td>4.2813902858562<\/td>\n<\/tr>\n
laboratory studies<\/td>4.2813902858562<\/td>\n<\/tr>\n
lal h<\/td>4.2813902858562<\/td>\n<\/tr>\n
serologic antibodies<\/td>4.2813902858562<\/td>\n<\/tr>\n
forszpaniak c<\/td>4.2813902858562<\/td>\n<\/tr>\n
johnson rw<\/td>4.2813902858562<\/td>\n<\/tr>\n
three clinical trials<\/td>4.2796527757347<\/td>\n<\/tr>\n
prospective clinical trials<\/td>4.2796527757347<\/td>\n<\/tr>\n
few isolated skin lesions<\/td>4.256307646096<\/td>\n<\/tr>\n
varicella-zoster virus dna<\/td>4.2513258303959<\/td>\n<\/tr>\n
nondrug measures<\/td>4.2294850537623<\/td>\n<\/tr>\n
acute disease phase<\/td>4.2160379991699<\/td>\n<\/tr>\n
zoe-70 study group<\/td>4.2140337012003<\/td>\n<\/tr>\n
zoe-50 study group<\/td>4.2140337012003<\/td>\n<\/tr>\n
serious adverse effects<\/td>4.1998684144302<\/td>\n<\/tr>\n
severe symptoms<\/td>4.1617914502878<\/td>\n<\/tr>\n
polymerase chain reaction<\/td>4.1601676461038<\/td>\n<\/tr>\n
adjacent dermatomes<\/td>4.1195342878142<\/td>\n<\/tr>\n
same time<\/td>4.1195342878142<\/td>\n<\/tr>\n
topical antiviral preparations<\/td>4.1034303767613<\/td>\n<\/tr>\n
infectious complications<\/td>4.090623489235<\/td>\n<\/tr>\n
potential ocular involvement<\/td>4.0898524685786<\/td>\n<\/tr>\n
shingles vaccines<\/td>4.0648138508249<\/td>\n<\/tr>\n
aggressive pain management<\/td>4.0167507341439<\/td>\n<\/tr>\n
betts rf<\/td>4<\/td>\n<\/tr>\n
large area of skin involvement<\/td>3.9422986842475<\/td>\n<\/tr>\n
increased skin sensitivity<\/td>3.9398401381041<\/td>\n<\/tr>\n
reynolds ma<\/td>3.9359793425309<\/td>\n<\/tr>\n
vaccination decisions<\/td>3.9359793425309<\/td>\n<\/tr>\n
bean b<\/td>3.9359793425309<\/td>\n<\/tr>\n
zhang jh<\/td>3.9359793425309<\/td>\n<\/tr>\n
tyring sk<\/td>3.9359793425309<\/td>\n<\/tr>\n
does childhood vaccination<\/td>3.9148676411689<\/td>\n<\/tr>\n
other possible symptoms<\/td>3.9002320242577<\/td>\n<\/tr>\n
central nervous system angiitis<\/td>3.8587145198412<\/td>\n<\/tr>\n
clear cause of shingles<\/td>3.8538131016031<\/td>\n<\/tr>\n
acute vision changes<\/td>3.8538131016031<\/td>\n<\/tr>\n
bacterial infection<\/td>3.8512851068431<\/td>\n<\/tr>\n
oral corticosteroids<\/td>3.8336586254776<\/td>\n<\/tr>\n
potential use<\/td>3.8336586254776<\/td>\n<\/tr>\n
postherpetic neuralgia?fewer patients<\/td>3.822602143583<\/td>\n<\/tr>\n
uncontrolled clinical trials<\/td>3.8127371719878<\/td>\n<\/tr>\n
hospital infection control practices advisory committee<\/td>3.80596150237<\/td>\n<\/tr>\n
such neurologic complications<\/td>3.8027429028336<\/td>\n<\/tr>\n
prednisone therapy<\/td>3.7976578442319<\/td>\n<\/tr>\n
common adverse effects<\/td>3.7416573867739<\/td>\n<\/tr>\n
whitley rj<\/td>3.7224194364084<\/td>\n<\/tr>\n
facial nerve<\/td>3.7224194364084<\/td>\n<\/tr>\n
percentage of children<\/td>3.7224194364084<\/td>\n<\/tr>\n
clinical outcome<\/td>3.7224194364084<\/td>\n<\/tr>\n
clinical presentation<\/td>3.7224194364084<\/td>\n<\/tr>\n
hospital rooms<\/td>3.7224194364084<\/td>\n<\/tr>\n
kim dk<\/td>3.7224194364084<\/td>\n<\/tr>\n
mckendrick mw<\/td>3.7224194364084<\/td>\n<\/tr>\n
first division<\/td>3.7224194364084<\/td>\n<\/tr>\n
seward jf<\/td>3.7224194364084<\/td>\n<\/tr>\n
anecdotal experience<\/td>3.7224194364084<\/td>\n<\/tr>\n
safety trial<\/td>3.6423205736757<\/td>\n<\/tr>\n
weakened immune system<\/td>3.6342411856643<\/td>\n<\/tr>\n
typical rash<\/td>3.6002057436785<\/td>\n<\/tr>\n
follow-up studies<\/td>3.6002057436785<\/td>\n<\/tr>\n
double-blind randomized controlled trial<\/td>3.5520935491791<\/td>\n<\/tr>\n
initial therapy<\/td>3.5341188430494<\/td>\n<\/tr>\n
improved therapy<\/td>3.5341188430494<\/td>\n<\/tr>\n
j am geriatr soc<\/td>3.4904525651001<\/td>\n<\/tr>\n
studies of recipients<\/td>3.4820045452271<\/td>\n<\/tr>\n
tricyclic antidepressants<\/td>3.4641016151377<\/td>\n<\/tr>\n
oral prednisone<\/td>3.4641016151377<\/td>\n<\/tr>\n
appropriate specialists<\/td>3.4641016151377<\/td>\n<\/tr>\n
age-related weakening<\/td>3.4641016151377<\/td>\n<\/tr>\n
air samples<\/td>3.4641016151377<\/td>\n<\/tr>\n
freezer storage<\/td>3.4641016151377<\/td>\n<\/tr>\n
laskin ol<\/td>3.4641016151377<\/td>\n<\/tr>\n
immunization schedule<\/td>3.4641016151377<\/td>\n<\/tr>\n
initial treatment<\/td>3.4641016151377<\/td>\n<\/tr>\n
diabetes mellitus<\/td>3.4641016151377<\/td>\n<\/tr>\n
steinberg sp<\/td>3.4641016151377<\/td>\n<\/tr>\n
use of corticosteroids<\/td>3.4641016151377<\/td>\n<\/tr>\n
bialek sr<\/td>3.4641016151377<\/td>\n<\/tr>\n
atypical presentations<\/td>3.4641016151377<\/td>\n<\/tr>\n
global perspective<\/td>3.4641016151377<\/td>\n<\/tr>\n
yawn bp<\/td>3.4641016151377<\/td>\n<\/tr>\n
foulks gn<\/td>3.4641016151377<\/td>\n<\/tr>\n
dworkin rh<\/td>3.4641016151377<\/td>\n<\/tr>\n
computed tomography<\/td>3.4641016151377<\/td>\n<\/tr>\n
sy ls<\/td>3.4641016151377<\/td>\n<\/tr>\n
national health<\/td>3.4397906282504<\/td>\n<\/tr>\n
population?based cohort study<\/td>3.4199518933534<\/td>\n<\/tr>\n
smith n<\/td>3.3895612242702<\/td>\n<\/tr>\n
aintablian n<\/td>3.3895612242702<\/td>\n<\/tr>\n
aggarwal n<\/td>3.3895612242702<\/td>\n<\/tr>\n
erskine n<\/td>3.3895612242702<\/td>\n<\/tr>\n
chen n<\/td>3.3895612242702<\/td>\n<\/tr>\n
typical skin eruption<\/td>3.3818572012642<\/td>\n<\/tr>\n
painful rash<\/td>3.3503689588345<\/td>\n<\/tr>\n
characteristic rash<\/td>3.3503689588345<\/td>\n<\/tr>\n
tyring s. open-label study of valacyclovir<\/td>3.31445401734<\/td>\n<\/tr>\n
retinal detachment<\/td>3.3097509196469<\/td>\n<\/tr>\n
cochrane review<\/td>3.3097509196469<\/td>\n<\/tr>\n
retinal tissue<\/td>3.3097509196469<\/td>\n<\/tr>\n
zostavax efficacy<\/td>3.2531531233956<\/td>\n<\/tr>\n
common adverse effect of rzv<\/td>3.2531531233956<\/td>\n<\/tr>\n
rzv group<\/td>3.2531531233956<\/td>\n<\/tr>\n
disease course<\/td>3.2237097954706<\/td>\n<\/tr>\n
risk of cancer<\/td>3.2010858729437<\/td>\n<\/tr>\n
\u00c2\u00bf therapy<\/td>3.1934368675747<\/td>\n<\/tr>\n
randomised controlled trial<\/td>3.1911262493545<\/td>\n<\/tr>\n
health care professional<\/td>3.1664800441388<\/td>\n<\/tr>\n
89.8 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
97.2 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
61.1 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
99.2 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
8.9 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
19.3 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
9.0 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
17.5 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
66.5 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
51.3 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
1.4 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
25.7 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
90.6 percent<\/td>3.1622776601684<\/td>\n<\/tr>\n
systematic review of incidence<\/td>3.14083560495<\/td>\n<\/tr>\n
surveillance of vaccination coverage<\/td>3.14083560495<\/td>\n<\/tr>\n
use steroids<\/td>3.1301691601466<\/td>\n<\/tr>\n
successful treatment<\/td>3.1301691601466<\/td>\n<\/tr>\n
overlap of lesions<\/td>3.1301691601466<\/td>\n<\/tr>\n
u.s. adults<\/td>3.1301691601466<\/td>\n<\/tr>\n
thorough history<\/td>3.1301691601466<\/td>\n<\/tr>\n
nonhemorrhagic lesions<\/td>3.1301691601466<\/td>\n<\/tr>\n
susceptible immunocompromised persons<\/td>3.0861636884341<\/td>\n<\/tr>\n
limited cutaneous involvement<\/td>3.0825813601419<\/td>\n<\/tr>\n
97.3 percent of persons<\/td>3.080070288241<\/td>\n<\/tr>\n
many patients<\/td>3.080070288241<\/td>\n<\/tr>\n
cutaneous vesicles<\/td>3.0628143136088<\/td>\n<\/tr>\n
cerebral vasculopathy<\/td>3.0628143136088<\/td>\n<\/tr>\n
primary infection<\/td>3.0628143136088<\/td>\n<\/tr>\n
common complication<\/td>3.0274001040351<\/td>\n<\/tr>\n
wash rash<\/td>3.0274001040351<\/td>\n<\/tr>\n
itchy rash<\/td>3.0274001040351<\/td>\n<\/tr>\n
side effects<\/td>3.0274001040351<\/td>\n<\/tr>\n
prospective studies<\/td>3.0274001040351<\/td>\n<\/tr>\n
high efficacy<\/td>3.0274001040351<\/td>\n<\/tr>\n
clinical slide set<\/td>3.0261714988458<\/td>\n<\/tr>\n
painful red rash<\/td>3.0182390421613<\/td>\n<\/tr>\n
retinal biopsy specimens<\/td>2.9937951655239<\/td>\n<\/tr>\n
national immunization survey<\/td>2.9937951655239<\/td>\n<\/tr>\n
zhang d<\/td>2.9906975624424<\/td>\n<\/tr>\n
placebo-controlled trials<\/td>2.9906975624424<\/td>\n<\/tr>\n
placebo-controlled trial of oxycodone<\/td>2.9506927476736<\/td>\n<\/tr>\n
affected nerve<\/td>2.9129506302439<\/td>\n<\/tr>\n
optimal use<\/td>2.9129506302439<\/td>\n<\/tr>\n
systemic effects<\/td>2.8925076085191<\/td>\n<\/tr>\n
low risk<\/td>2.8925076085191<\/td>\n<\/tr>\n
9.4 percent of recipients<\/td>2.8925076085191<\/td>\n<\/tr>\n
16.5 percent of recipients<\/td>2.8925076085191<\/td>\n<\/tr>\n
percent of recipients<\/td>2.8925076085191<\/td>\n<\/tr>\n
betts r<\/td>2.8716217110259<\/td>\n<\/tr>\n
latent infection<\/td>2.8502698827718<\/td>\n<\/tr>\n
other medicines<\/td>2.8502698827718<\/td>\n<\/tr>\n
other benefits<\/td>2.8502698827718<\/td>\n<\/tr>\n
few other diseases<\/td>2.8429702849739<\/td>\n<\/tr>\n
visceral involvement<\/td>2.8394115144337<\/td>\n<\/tr>\n
zhou d<\/td>2.8284271247462<\/td>\n<\/tr>\n
hemiparesis contralateral<\/td>2.8284271247462<\/td>\n<\/tr>\n
1.5 g<\/td>2.8284271247462<\/td>\n<\/tr>\n
mental status changes<\/td>2.8210130123402<\/td>\n<\/tr>\n
vision changes<\/td>2.8173132472613<\/td>\n<\/tr>\n
common systemic effects<\/td>2.8077989890847<\/td>\n<\/tr>\n
kang y. vaccination coverage<\/td>2.8057011040133<\/td>\n<\/tr>\n
national immunization survey-child<\/td>2.7981664143395<\/td>\n<\/tr>\n
one side<\/td>2.7831576837137<\/td>\n<\/tr>\n
ophthalmic symptoms<\/td>2.7831576837137<\/td>\n<\/tr>\n
certain ophthalmologic complications<\/td>2.766175108537<\/td>\n<\/tr>\n
pathogenesis of diffuse disease<\/td>2.7494592739972<\/td>\n<\/tr>\n
department of health<\/td>2.7355647997348<\/td>\n<\/tr>\n
superior efficacy<\/td>2.7355647997348<\/td>\n<\/tr>\n
health professionals<\/td>2.7355647997348<\/td>\n<\/tr>\n
life-threatening secondary bacterial infection<\/td>2.677321285993<\/td>\n<\/tr>\n
meta-analysis of risk factors<\/td>2.6546748825543<\/td>\n<\/tr>\n
erythematous maculopapular rash<\/td>2.6366746651365<\/td>\n<\/tr>\n
use of gloves<\/td>2.632148025905<\/td>\n<\/tr>\n
dosing schedules<\/td>2.632148025905<\/td>\n<\/tr>\n
corticosteroid use<\/td>2.632148025905<\/td>\n<\/tr>\n
first dose<\/td>2.632148025905<\/td>\n<\/tr>\n
late complication<\/td>2.632148025905<\/td>\n<\/tr>\n
additional laboratory<\/td>2.632148025905<\/td>\n<\/tr>\n
blood test<\/td>2.632148025905<\/td>\n<\/tr>\n
as-needed dosing<\/td>2.632148025905<\/td>\n<\/tr>\n
afferent nerve<\/td>2.632148025905<\/td>\n<\/tr>\n
dosing regimen<\/td>2.632148025905<\/td>\n<\/tr>\n
contact isolation<\/td>2.632148025905<\/td>\n<\/tr>\n
clin res ed<\/td>2.6207413942089<\/td>\n<\/tr>\n
other signs<\/td>2.5755095769014<\/td>\n<\/tr>\n
hiv infection<\/td>2.5755095769014<\/td>\n<\/tr>\n
recommended immunization schedule<\/td>2.5697965868507<\/td>\n<\/tr>\n
control hosp epidemiol<\/td>2.5697965868507<\/td>\n<\/tr>\n
public health rep<\/td>2.557759296802<\/td>\n<\/tr>\n
intravenous antivirals<\/td>2.5457298950218<\/td>\n<\/tr>\n
histopathologic studies<\/td>2.5457298950218<\/td>\n<\/tr>\n
immunocompetent hosts<\/td>2.5457298950218<\/td>\n<\/tr>\n
topical corticosteroids<\/td>2.5457298950218<\/td>\n<\/tr>\n
alternate diagnosis<\/td>2.5148668593659<\/td>\n<\/tr>\n
examination of csf<\/td>2.5148668593659<\/td>\n<\/tr>\n
examination of links<\/td>2.5148668593659<\/td>\n<\/tr>\n
strokelike symptoms<\/td>2.5148668593659<\/td>\n<\/tr>\n
current symptoms<\/td>2.5148668593659<\/td>\n<\/tr>\n
gastrointestinal symptoms<\/td>2.5148668593659<\/td>\n<\/tr>\n
ophthalmic involvement<\/td>2.4989993994394<\/td>\n<\/tr>\n
cobo m<\/td>2.4989993994394<\/td>\n<\/tr>\n
characteristic funduscopic examination<\/td>2.4928828716784<\/td>\n<\/tr>\n
recent cochrane review<\/td>2.4928828716784<\/td>\n<\/tr>\n
intraocular inflammatory changes<\/td>2.4643818583473<\/td>\n<\/tr>\n
drug administration<\/td>2.4494897427832<\/td>\n<\/tr>\n
cunningham a<\/td>2.4494897427832<\/td>\n<\/tr>\n
supportive care<\/td>2.4494897427832<\/td>\n<\/tr>\n
facial muscle weakness<\/td>2.4494897427832<\/td>\n<\/tr>\n
o fhalloran a<\/td>2.4494897427832<\/td>\n<\/tr>\n
ifle r<\/td>2.4147364027664<\/td>\n<\/tr>\n
ashton r<\/td>2.4147364027664<\/td>\n<\/tr>\n
kay r<\/td>2.4147364027664<\/td>\n<\/tr>\n
farmer r<\/td>2.4147364027664<\/td>\n<\/tr>\n
schlag r<\/td>2.4147364027664<\/td>\n<\/tr>\n
gress r<\/td>2.4147364027664<\/td>\n<\/tr>\n
merlin r<\/td>2.4147364027664<\/td>\n<\/tr>\n
possible cause of tia<\/td>2.401873910352<\/td>\n<\/tr>\n
bill part d directly?and<\/td>2.3784142300054<\/td>\n<\/tr>\n
frequent dosing<\/td>2.3784142300054<\/td>\n<\/tr>\n
kruszon-moran d<\/td>2.3784142300054<\/td>\n<\/tr>\n
international blood<\/td>2.3784142300054<\/td>\n<\/tr>\n
yankey d<\/td>2.3784142300054<\/td>\n<\/tr>\n
immune response<\/td>2.3784142300054<\/td>\n<\/tr>\n
vista trial investigators<\/td>2.3672935308725<\/td>\n<\/tr>\n
anticholinergic side effects<\/td>2.3490100793233<\/td>\n<\/tr>\n
median duration<\/td>2.3403473193207<\/td>\n<\/tr>\n
age groups<\/td>2.3403473193207<\/td>\n<\/tr>\n
systemic reactions<\/td>2.3403473193207<\/td>\n<\/tr>\n
kurland mj<\/td>2.3403473193207<\/td>\n<\/tr>\n
involved dermatomes<\/td>2.3403473193207<\/td>\n<\/tr>\n
kenneth schmader<\/td>2.3403473193207<\/td>\n<\/tr>\n
diagnostic challenges<\/td>2.3403473193207<\/td>\n<\/tr>\n
dr. schmader<\/td>2.3403473193207<\/td>\n<\/tr>\n
magnetic resonance imaging<\/td>2.334815148678<\/td>\n<\/tr>\n
serious problems<\/td>2.3003266337912<\/td>\n<\/tr>\n
intravenous ganciclovir<\/td>2.3003266337912<\/td>\n<\/tr>\n
kim sj<\/td>2.3003266337912<\/td>\n<\/tr>\n
peripheral nerve palsies<\/td>2.2894284851067<\/td>\n<\/tr>\n
altered mental status<\/td>2.2894284851067<\/td>\n<\/tr>\n
primary care providers<\/td>2.2894284851067<\/td>\n<\/tr>\n
wade a<\/td>2.2795070569548<\/td>\n<\/tr>\n
potential benefits<\/td>2.2795070569548<\/td>\n<\/tr>\n
wollan p<\/td>2.2795070569548<\/td>\n<\/tr>\n
epidural injection<\/td>2.2795070569548<\/td>\n<\/tr>\n
vazquez m<\/td>2.2581008643532<\/td>\n<\/tr>\n
douha m<\/td>2.2581008643532<\/td>\n<\/tr>\n
babb-tarbox m<\/td>2.2581008643532<\/td>\n<\/tr>\n
heng m<\/td>2.2581008643532<\/td>\n<\/tr>\n
tomlinson m<\/td>2.2581008643532<\/td>\n<\/tr>\n
simultaneous involvement<\/td>2.2581008643532<\/td>\n<\/tr>\n
kovac m<\/td>2.2581008643532<\/td>\n<\/tr>\n
tomblyn m<\/td>2.2581008643532<\/td>\n<\/tr>\n
patel m<\/td>2.2581008643532<\/td>\n<\/tr>\n
kropff m<\/td>2.2581008643532<\/td>\n<\/tr>\n
permanent facial muscle weakness<\/td>2.2461919979205<\/td>\n<\/tr>\n
three 7-day regimens of famciclovir<\/td>2.2427067839403<\/td>\n<\/tr>\n
3.2 years<\/td>2.2360679774998<\/td>\n<\/tr>\n
3.1 years<\/td>2.2360679774998<\/td>\n<\/tr>\n
3.7 years<\/td>2.2360679774998<\/td>\n<\/tr>\n
tyring s<\/td>2.2360679774998<\/td>\n<\/tr>\n
nutrition examination survey<\/td>2.2209061548523<\/td>\n<\/tr>\n
active viral replication<\/td>2.2209061548523<\/td>\n<\/tr>\n
side ipsilateral<\/td>2.2133638394006<\/td>\n<\/tr>\n
second dose<\/td>2.2133638394006<\/td>\n<\/tr>\n
proximate cause<\/td>2.2133638394006<\/td>\n<\/tr>\n
young adults<\/td>2.2133638394006<\/td>\n<\/tr>\n
rare patient<\/td>2.2133638394006<\/td>\n<\/tr>\n
functional status<\/td>2.2133638394006<\/td>\n<\/tr>\n
levin l<\/td>2.2133638394006<\/td>\n<\/tr>\n
direct contact<\/td>2.2133638394006<\/td>\n<\/tr>\n
marrow research<\/td>2.2133638394006<\/td>\n<\/tr>\n
sacral area<\/td>2.2133638394006<\/td>\n<\/tr>\n
anecdotal reports<\/td>2.2133638394006<\/td>\n<\/tr>\n
weeks of onset<\/td>2.2133638394006<\/td>\n<\/tr>\n
improved preservation of vision<\/td>2.1822472719434<\/td>\n<\/tr>\n
mayo clin proc<\/td>2.1822472719434<\/td>\n<\/tr>\n
curr eye res<\/td>2.1822472719434<\/td>\n<\/tr>\n
mmwr recomm rep<\/td>2.1544346900319<\/td>\n<\/tr>\n
national institute of allergy<\/td>2.1544346900319<\/td>\n<\/tr>\n
single 0.65-ml dose<\/td>2.1398263878673<\/td>\n<\/tr>\n
resonant impurity states<\/td>2.1398263878673<\/td>\n<\/tr>\n
large surface area<\/td>2.1398263878673<\/td>\n<\/tr>\n
simplified dosing schedules<\/td>2.1398263878673<\/td>\n<\/tr>\n
cranial nerve ganglia<\/td>2.1398263878673<\/td>\n<\/tr>\n
increased sensitivity<\/td>2.1147425268811<\/td>\n<\/tr>\n
daily famciclovir<\/td>2.1147425268811<\/td>\n<\/tr>\n
lack of evidence<\/td>2.1147425268811<\/td>\n<\/tr>\n
diagnostic tests<\/td>2.1147425268811<\/td>\n<\/tr>\n
anti-tnf-alpha agents<\/td>2.1147425268811<\/td>\n<\/tr>\n
involved dermatome<\/td>2.1147425268811<\/td>\n<\/tr>\n
compared valacyclovir<\/td>2.1147425268811<\/td>\n<\/tr>\n
diagnostic procedures<\/td>2.1147425268811<\/td>\n<\/tr>\n
lack of need<\/td>2.1147425268811<\/td>\n<\/tr>\n
relative lack<\/td>2.1147425268811<\/td>\n<\/tr>\n
general information<\/td>2.1147425268811<\/td>\n<\/tr>\n
biol blood marrow transplant<\/td>2.1039790110173<\/td>\n<\/tr>\n
peripheral blood stem cells<\/td>2.1039790110173<\/td>\n<\/tr>\n
permanent pigment changes<\/td>2.0927300685678<\/td>\n<\/tr>\n
viral strain identification<\/td>2.0757816311124<\/td>\n<\/tr>\n
jumaan a<\/td>2.0597671439071<\/td>\n<\/tr>\n
moore k<\/td>2.0597671439071<\/td>\n<\/tr>\n
mruthyunjaya p<\/td>2.0597671439071<\/td>\n<\/tr>\n
potential pregnancy<\/td>2.0597671439071<\/td>\n<\/tr>\n
morton p<\/td>2.0597671439071<\/td>\n<\/tr>\n
saddier p<\/td>2.0597671439071<\/td>\n<\/tr>\n
sacral dermatomes<\/td>2.0597671439071<\/td>\n<\/tr>\n
hunter p<\/td>2.0597671439071<\/td>\n<\/tr>\n
herzer p<\/td>2.0597671439071<\/td>\n<\/tr>\n
strangfeld a<\/td>2.0597671439071<\/td>\n<\/tr>\n
sepkowitz k<\/td>2.0597671439071<\/td>\n<\/tr>\n
durham va medical center<\/td>2.0597671439071<\/td>\n<\/tr>\n
gnann jw<\/td>2.0597671439071<\/td>\n<\/tr>\n
bhaskaran k<\/td>2.0597671439071<\/td>\n<\/tr>\n
liebhaber a<\/td>2.0597671439071<\/td>\n<\/tr>\n
isolation precautions<\/td>2.0597671439071<\/td>\n<\/tr>\n
steroids?and persons<\/td>2.0597671439071<\/td>\n<\/tr>\n
guo a<\/td>2.0597671439071<\/td>\n<\/tr>\n
potential risks<\/td>2.0597671439071<\/td>\n<\/tr>\n
blinded rct<\/td>2.0597671439071<\/td>\n<\/tr>\n
third rct<\/td>2.0597671439071<\/td>\n<\/tr>\n
pcr assay<\/td>2.0597671439071<\/td>\n<\/tr>\n
potential barriers<\/td>2.0597671439071<\/td>\n<\/tr>\n
red blisters<\/td>2.0597671439071<\/td>\n<\/tr>\n
challenging cases<\/td>2.0597671439071<\/td>\n<\/tr>\n
arora a<\/td>2.0597671439071<\/td>\n<\/tr>\n
intact persons<\/td>2.0597671439071<\/td>\n<\/tr>\n
rockwitz k<\/td>2.0597671439071<\/td>\n<\/tr>\n
continued new vesicle formation<\/td>2.0565711885958<\/td>\n<\/tr>\n
results of pcr assay<\/td>2.0396489026555<\/td>\n<\/tr>\n
gnann jw jr<\/td>2.0396489026555<\/td>\n<\/tr>\n
0.5-ml intramuscular injection<\/td>2.0396489026555<\/td>\n<\/tr>\n
focal neurologic findings<\/td>2.0396489026555<\/td>\n<\/tr>\n
concomitant administration of zostavax<\/td>2.0396489026555<\/td>\n<\/tr>\n
general practice<\/td>2<\/td>\n<\/tr>\n
inferior pharmacokinetic characteristics<\/td>2<\/td>\n<\/tr>\n
u.s. food<\/td>2<\/td>\n<\/tr>\n
anti?tumor necrosis factor<\/td>2<\/td>\n<\/tr>\n
primary dermatome<\/td>2<\/td>\n<\/tr>\n
cerebral arteries<\/td>2<\/td>\n<\/tr>\n
uptake of rzv<\/td>2<\/td>\n<\/tr>\n
nondrug therapies<\/td>2<\/td>\n<\/tr>\n
white je<\/td>1.9679896712654<\/td>\n<\/tr>\n
zhang q<\/td>1.9679896712654<\/td>\n<\/tr>\n
life-threatening allergy<\/td>1.9679896712654<\/td>\n<\/tr>\n
sutphin je<\/td>1.9679896712654<\/td>\n<\/tr>\n
hematopoietic cell transplantation recipients<\/td>1.9668942118313<\/td>\n<\/tr>\n
duke university medical center<\/td>1.9579730911015<\/td>\n<\/tr>\n
magnetic resonance angiography<\/td>1.9441612972397<\/td>\n<\/tr>\n
richter c<\/td>1.9343364202677<\/td>\n<\/tr>\n
johnson g<\/td>1.9343364202677<\/td>\n<\/tr>\n
bakri sj<\/td>1.9343364202677<\/td>\n<\/tr>\n
jacobsen sj<\/td>1.9343364202677<\/td>\n<\/tr>\n
vesikari t<\/td>1.9343364202677<\/td>\n<\/tr>\n
pilishvili t<\/td>1.9343364202677<\/td>\n<\/tr>\n
soong sj<\/td>1.9343364202677<\/td>\n<\/tr>\n
topical creams<\/td>1.9343364202677<\/td>\n<\/tr>\n
topical capsaicin<\/td>1.9343364202677<\/td>\n<\/tr>\n
tran h<\/td>1.9343364202677<\/td>\n<\/tr>\n
weiss h<\/td>1.9343364202677<\/td>\n<\/tr>\n
einsele h<\/td>1.9343364202677<\/td>\n<\/tr>\n
common sentinel<\/td>1.9343364202677<\/td>\n<\/tr>\n
gzoster h<\/td>1.9343364202677<\/td>\n<\/tr>\n
chiller t<\/td>1.9343364202677<\/td>\n<\/tr>\n
kiefe c<\/td>1.9343364202677<\/td>\n<\/tr>\n
ulbricht c<\/td>1.9343364202677<\/td>\n<\/tr>\n
claeys c<\/td>1.9343364202677<\/td>\n<\/tr>\n
clayton t<\/td>1.9343364202677<\/td>\n<\/tr>\n
disseminated rashes<\/td>1.9343364202677<\/td>\n<\/tr>\n
adult u.s. population<\/td>1.9063685859939<\/td>\n<\/tr>\n
middle cerebral artery<\/td>1.9063685859939<\/td>\n<\/tr>\n
zhu c. corticosteroids<\/td>1.9063685859939<\/td>\n<\/tr>\n
clear vesicles<\/td>1.8612097182042<\/td>\n<\/tr>\n
epidural steroids<\/td>1.8612097182042<\/td>\n<\/tr>\n
noncontiguous dermatomes<\/td>1.8612097182042<\/td>\n<\/tr>\n
time frame<\/td>1.8612097182042<\/td>\n<\/tr>\n
strict isolation<\/td>1.8612097182042<\/td>\n<\/tr>\n
many people<\/td>1.8612097182042<\/td>\n<\/tr>\n
previous exposure<\/td>1.8612097182042<\/td>\n<\/tr>\n
role of corticosteroids<\/td>1.8612097182042<\/td>\n<\/tr>\n
case reports<\/td>1.8612097182042<\/td>\n<\/tr>\n
body fight<\/td>1.8612097182042<\/td>\n<\/tr>\n
shpilberg o<\/td>1.8612097182042<\/td>\n<\/tr>\n
over-the-counter medications<\/td>1.8612097182042<\/td>\n<\/tr>\n
small children<\/td>1.8612097182042<\/td>\n<\/tr>\n
immunogenicity profile<\/td>1.8612097182042<\/td>\n<\/tr>\n
appearance of blisters<\/td>1.8612097182042<\/td>\n<\/tr>\n
reports grants<\/td>1.8612097182042<\/td>\n<\/tr>\n
placebo groups<\/td>1.8612097182042<\/td>\n<\/tr>\n
several days<\/td>1.8612097182042<\/td>\n<\/tr>\n
affected dermatome<\/td>1.8612097182042<\/td>\n<\/tr>\n
morrison va<\/td>1.8612097182042<\/td>\n<\/tr>\n
godeaux o<\/td>1.8612097182042<\/td>\n<\/tr>\n
eye evaluation<\/td>1.8612097182042<\/td>\n<\/tr>\n
additional therapies<\/td>1.8612097182042<\/td>\n<\/tr>\n
high sensitivity<\/td>1.8612097182042<\/td>\n<\/tr>\n
approved valacyclovir dosage<\/td>1.8493111942973<\/td>\n<\/tr>\n
mmwr surveill summ<\/td>1.8493111942973<\/td>\n<\/tr>\n
consistent diagnostic criterion<\/td>1.8493111942973<\/td>\n<\/tr>\n
transient ischemic attacks<\/td>1.8493111942973<\/td>\n<\/tr>\n
basic symptomatic measures<\/td>1.8493111942973<\/td>\n<\/tr>\n
antimicrob agents chemother<\/td>1.8493111942973<\/td>\n<\/tr>\n
short-term persistence substudy<\/td>1.8171205928321<\/td>\n<\/tr>\n
small vessel vasculitis<\/td>1.8171205928321<\/td>\n<\/tr>\n
short-acting narcotic analgesics<\/td>1.7817974362807<\/td>\n<\/tr>\n
phys rev lett<\/td>1.7817974362807<\/td>\n<\/tr>\n
american academy of ophthalmology<\/td>1.7817974362807<\/td>\n<\/tr>\n
san miguel jf<\/td>1.7817974362807<\/td>\n<\/tr>\n
stokley s<\/td>1.7782794100389<\/td>\n<\/tr>\n
yeh s<\/td>1.7782794100389<\/td>\n<\/tr>\n
aboutlabeti s<\/td>1.7782794100389<\/td>\n<\/tr>\n
moeckesch b<\/td>1.7782794100389<\/td>\n<\/tr>\n
nahlik je<\/td>1.7782794100389<\/td>\n<\/tr>\n
kerzner b<\/td>1.7782794100389<\/td>\n<\/tr>\n
medlineplus information<\/td>1.7782794100389<\/td>\n<\/tr>\n
nagel ma<\/td>1.7782794100389<\/td>\n<\/tr>\n
cerebrovascular events<\/td>1.7782794100389<\/td>\n<\/tr>\n
dimopoulos ma<\/td>1.7782794100389<\/td>\n<\/tr>\n
thorne je<\/td>1.7782794100389<\/td>\n<\/tr>\n
auricle?indicate ramsay hunt syndrome<\/td>1.7692284081335<\/td>\n<\/tr>\n
author thanks jennifer f. wilson<\/td>1.7411011265923<\/td>\n<\/tr>\n
wade jc<\/td>1.7320508075689<\/td>\n<\/tr>\n
over-the-counter medicines<\/td>1.7320508075689<\/td>\n<\/tr>\n
preferred test<\/td>1.7320508075689<\/td>\n<\/tr>\n
preferred alternative<\/td>1.7320508075689<\/td>\n<\/tr>\n
2-dose regimen<\/td>1.7320508075689<\/td>\n<\/tr>\n
local reactions<\/td>1.7320508075689<\/td>\n<\/tr>\n
as-needed basis<\/td>1.7320508075689<\/td>\n<\/tr>\n
curr opin neurol<\/td>1.6983813295649<\/td>\n<\/tr>\n
past several decades<\/td>1.6983813295649<\/td>\n<\/tr>\n
mg\/kg of body weight<\/td>1.6983813295649<\/td>\n<\/tr>\n
mg of methylprednisolone acetate<\/td>1.6983813295649<\/td>\n<\/tr>\n
van wijck aj<\/td>1.6983813295649<\/td>\n<\/tr>\n
internal carotid artery<\/td>1.6983813295649<\/td>\n<\/tr>\n
van essen ga<\/td>1.6983813295649<\/td>\n<\/tr>\n
general feeling<\/td>1.6817928305074<\/td>\n<\/tr>\n
toxic dermatitis<\/td>1.6817928305074<\/td>\n<\/tr>\n
ambinder rf<\/td>1.6817928305074<\/td>\n<\/tr>\n
eligible people<\/td>1.6817928305074<\/td>\n<\/tr>\n
corey l<\/td>1.6817928305074<\/td>\n<\/tr>\n
chamberlin cj<\/td>1.6817928305074<\/td>\n<\/tr>\n
clusters of vesicles<\/td>1.6817928305074<\/td>\n<\/tr>\n
rare disorder<\/td>1.6817928305074<\/td>\n<\/tr>\n
research setting<\/td>1.6817928305074<\/td>\n<\/tr>\n
ophthalmology consultation<\/td>1.6817928305074<\/td>\n<\/tr>\n
stolker rj<\/td>1.6817928305074<\/td>\n<\/tr>\n
previous version<\/td>1.6817928305074<\/td>\n<\/tr>\n
high-dose steroids<\/td>1.6817928305074<\/td>\n<\/tr>\n
rare occasions<\/td>1.6817928305074<\/td>\n<\/tr>\n
positive results<\/td>1.6817928305074<\/td>\n<\/tr>\n
smeeth l<\/td>1.6817928305074<\/td>\n<\/tr>\n
subsequent pustulation<\/td>1.6817928305074<\/td>\n<\/tr>\n
absence of pleocytosis<\/td>1.6817928305074<\/td>\n<\/tr>\n
lymphocytic pleocytosis<\/td>1.6817928305074<\/td>\n<\/tr>\n
kalkman cj<\/td>1.6817928305074<\/td>\n<\/tr>\n
three times<\/td>1.6817928305074<\/td>\n<\/tr>\n
ragozzino mw<\/td>1.6817928305074<\/td>\n<\/tr>\n
acosta cj<\/td>1.6817928305074<\/td>\n<\/tr>\n
mononuclear pleocytosis<\/td>1.6817928305074<\/td>\n<\/tr>\n
bortezomib-based therapies<\/td>1.6817928305074<\/td>\n<\/tr>\n
million people<\/td>1.6817928305074<\/td>\n<\/tr>\n
prospective fashion<\/td>1.6817928305074<\/td>\n<\/tr>\n
analgesic medications<\/td>1.6817928305074<\/td>\n<\/tr>\n
wallace mr. detection<\/td>1.5874010519682<\/td>\n<\/tr>\n
cool astringent soaks<\/td>1.5874010519682<\/td>\n<\/tr>\n
comas j. observation<\/td>1.5874010519682<\/td>\n<\/tr>\n
health-related quality of life<\/td>1.5874010519682<\/td>\n<\/tr>\n
private insurance plans<\/td>1.5874010519682<\/td>\n<\/tr>\n
english word gbelt<\/td>1.5874010519682<\/td>\n<\/tr>\n
st sauver jl<\/td>1.5874010519682<\/td>\n<\/tr>\n
sensory neurons<\/td>1.5650845800733<\/td>\n<\/tr>\n
controlled-release oxycodone<\/td>1.5650845800733<\/td>\n<\/tr>\n
types of vaccines<\/td>1.5650845800733<\/td>\n<\/tr>\n
such manifestations<\/td>1.5650845800733<\/td>\n<\/tr>\n
elam-evans ld<\/td>1.5650845800733<\/td>\n<\/tr>\n
connor jd<\/td>1.5650845800733<\/td>\n<\/tr>\n
2-dose requirement<\/td>1.5650845800733<\/td>\n<\/tr>\n
mg of bupivacaine<\/td>1.5650845800733<\/td>\n<\/tr>\n
outpatient basis<\/td>1.5650845800733<\/td>\n<\/tr>\n
standard precautions<\/td>1.5650845800733<\/td>\n<\/tr>\n
localized sensations<\/td>1.5650845800733<\/td>\n<\/tr>\n
adult populations<\/td>1.5650845800733<\/td>\n<\/tr>\n
cobo lm<\/td>1.5650845800733<\/td>\n<\/tr>\n
kurland lt<\/td>1.5650845800733<\/td>\n<\/tr>\n
specific treatments<\/td>1.5650845800733<\/td>\n<\/tr>\n
perry ta<\/td>1.5650845800733<\/td>\n<\/tr>\n
latent state<\/td>1.5650845800733<\/td>\n<\/tr>\n
susceptible infants<\/td>1.5650845800733<\/td>\n<\/tr>\n
friedman dj<\/td>1.5650845800733<\/td>\n<\/tr>\n
huff jc<\/td>1.5650845800733<\/td>\n<\/tr>\n
cohen ji<\/td>1.5650845800733<\/td>\n<\/tr>\n
shafran sd<\/td>1.5650845800733<\/td>\n<\/tr>\n
bone cancer<\/td>1.5650845800733<\/td>\n<\/tr>\n
schoenberger sd<\/td>1.5650845800733<\/td>\n<\/tr>\n
rice as<\/td>1.5650845800733<\/td>\n<\/tr>\n
lopez as<\/td>1.5650845800733<\/td>\n<\/tr>\n
frequency increases<\/td>1.5650845800733<\/td>\n<\/tr>\n
cheng e<\/td>1.5650845800733<\/td>\n<\/tr>\n
williams ww<\/td>1.5650845800733<\/td>\n<\/tr>\n
mcquillan gm<\/td>1.5650845800733<\/td>\n<\/tr>\n
direct invasion<\/td>1.5650845800733<\/td>\n<\/tr>\n
white race<\/td>1.5650845800733<\/td>\n<\/tr>\n
gelb ld<\/td>1.5650845800733<\/td>\n<\/tr>\n
similar syndrome<\/td>1.5650845800733<\/td>\n<\/tr>\n
local anaesthetics<\/td>1.5650845800733<\/td>\n<\/tr>\n
mcgill ji<\/td>1.5650845800733<\/td>\n<\/tr>\n
virus?related vasculitis<\/td>1.5650845800733<\/td>\n<\/tr>\n
perry ho<\/td>1.5650845800733<\/td>\n<\/tr>\n
grohskopf la<\/td>1.5650845800733<\/td>\n<\/tr>\n
dermatomal distribution<\/td>1.5650845800733<\/td>\n<\/tr>\n
shapiro e<\/td>1.5650845800733<\/td>\n<\/tr>\n
frank infarction<\/td>1.5650845800733<\/td>\n<\/tr>\n
plant exposure<\/td>1.5650845800733<\/td>\n<\/tr>\n
williams hm<\/td>1.5650845800733<\/td>\n<\/tr>\n
galea sa<\/td>1.5650845800733<\/td>\n<\/tr>\n
meyers jd<\/td>1.5650845800733<\/td>\n<\/tr>\n
lee gm<\/td>1.5650845800733<\/td>\n<\/tr>\n
weakened immunity<\/td>1.5650845800733<\/td>\n<\/tr>\n
billing challenges<\/td>1.5650845800733<\/td>\n<\/tr>\n
brain infarction<\/td>1.5650845800733<\/td>\n<\/tr>\n
experienced ophthalmologist<\/td>1.5650845800733<\/td>\n<\/tr>\n
sensory nerves<\/td>1.5650845800733<\/td>\n<\/tr>\n
good alternative<\/td>1.5650845800733<\/td>\n<\/tr>\n
li q<\/td>1.5650845800733<\/td>\n<\/tr>\n
wollan pc<\/td>1.5650845800733<\/td>\n<\/tr>\n
intravitreal antivirals<\/td>1.5650845800733<\/td>\n<\/tr>\n
experienced physicians<\/td>1.5650845800733<\/td>\n<\/tr>\n
mcneil sa<\/td>1.5650845800733<\/td>\n<\/tr>\n
special considerations<\/td>1.5650845800733<\/td>\n<\/tr>\n
crane la<\/td>1.5650845800733<\/td>\n<\/tr>\n
cost?benefit considerations<\/td>1.5650845800733<\/td>\n<\/tr>\n
looney dj<\/td>1.5650845800733<\/td>\n<\/tr>\n
fluorescent antigen<\/td>1.4142135623731<\/td>\n<\/tr>\n
harvey pr<\/td>1.4142135623731<\/td>\n<\/tr>\n
disease-related immunosuppression<\/td>1.4142135623731<\/td>\n<\/tr>\n
neural blockade<\/td>1.4142135623731<\/td>\n<\/tr>\n
belongia ea<\/td>1.4142135623731<\/td>\n<\/tr>\n
khuageva nk<\/td>1.4142135623731<\/td>\n<\/tr>\n
lu pj<\/td>1.4142135623731<\/td>\n<\/tr>\n
fact sheet<\/td>1.4142135623731<\/td>\n<\/tr>\n
allogenic transplants<\/td>1.4142135623731<\/td>\n<\/tr>\n
straus se<\/td>1.4142135623731<\/td>\n<\/tr>\n
singleton ja<\/td>1.4142135623731<\/td>\n<\/tr>\n
keatley rm<\/td>1.4142135623731<\/td>\n<\/tr>\n
female sex<\/td>1.4142135623731<\/td>\n<\/tr>\n
significant fever<\/td>1.4142135623731<\/td>\n<\/tr>\n
dooling kl<\/td>1.4142135623731<\/td>\n<\/tr>\n
moons kg<\/td>1.4142135623731<\/td>\n<\/tr>\n
sharrar rg<\/td>1.4142135623731<\/td>\n<\/tr>\n
chu cp<\/td>1.4142135623731<\/td>\n<\/tr>\n
thomas sl<\/td>1.4142135623731<\/td>\n<\/tr>\n
dorsal root<\/td>1.4142135623731<\/td>\n<\/tr>\n
hales cm<\/td>1.4142135623731<\/td>\n<\/tr>\n
riley le<\/td>1.4142135623731<\/td>\n<\/tr>\n
mcdermott mp<\/td>1.4142135623731<\/td>\n<\/tr>\n
barbano rl<\/td>1.4142135623731<\/td>\n<\/tr>\n
hematogenous route<\/td>1.4142135623731<\/td>\n<\/tr>\n
quantum-well structures<\/td>1.4142135623731<\/td>\n<\/tr>\n
tseng hf<\/td>1.4142135623731<\/td>\n<\/tr>\n
proximal branches<\/td>1.4142135623731<\/td>\n<\/tr>\n
sweet ar<\/td>1.4142135623731<\/td>\n<\/tr>\n
andersen pl<\/td>1.4142135623731<\/td>\n<\/tr>\n
gershon aa<\/td>1.4142135623731<\/td>\n<\/tr>\n
madkan vk<\/td>1.4142135623731<\/td>\n<\/tr>\n
schmid ds<\/td>1.4142135623731<\/td>\n<\/tr>\n
only contraindication<\/td>1.4142135623731<\/td>\n<\/tr>\n
light touch<\/td>1.4142135623731<\/td>\n<\/tr>\n
gebremeskel bg<\/td>1.4142135623731<\/td>\n<\/tr>\n
known correlation<\/td>1.4142135623731<\/td>\n<\/tr>\n
oligoclonal bands<\/td>1.4142135623731<\/td>\n<\/tr>\n
nucleic acids<\/td>1.4142135623731<\/td>\n<\/tr>\n
neurotrophic keratitis<\/td>1.4142135623731<\/td>\n<\/tr>\n
average interval<\/td>1.4142135623731<\/td>\n<\/tr>\n
hurley lp<\/td>1.4142135623731<\/td>\n<\/tr>\n
t-cell count<\/td>1.4142135623731<\/td>\n<\/tr>\n
ortega-sanchez ir<\/td>1.4142135623731<\/td>\n<\/tr>\n
arbeit rd<\/td>1.4142135623731<\/td>\n<\/tr>\n
pappas pg<\/td>1.4142135623731<\/td>\n<\/tr>\n
lindley mc<\/td>1.4142135623731<\/td>\n<\/tr>\n
rheumatoid arthritis<\/td>1.4142135623731<\/td>\n<\/tr>\n
melton lj<\/td>1.4142135623731<\/td>\n<\/tr>\n
joesoef mr<\/td>1.4142135623731<\/td>\n<\/tr>\n
human services<\/td>1.4142135623731<\/td>\n<\/tr>\n
bmj open<\/td>1.4142135623731<\/td>\n<\/tr>\n
arterial stenosis<\/td>1.4142135623731<\/td>\n<\/tr>\n
barbarash ra<\/td>1.4142135623731<\/td>\n<\/tr>\n
cerebrospinal fluid<\/td>1.4142135623731<\/td>\n<\/tr>\n
protein level<\/td>1.4142135623731<\/td>\n<\/tr>\n
daley mf<\/td>1.4142135623731<\/td>\n<\/tr>\n
vitreous humor<\/td>1.4142135623731<\/td>\n<\/tr>\n
subacute delirium<\/td>1.4142135623731<\/td>\n<\/tr>\n
lasting damage<\/td>1.4142135623731<\/td>\n<\/tr>\n
hutchinson sign<\/td>1.4142135623731<\/td>\n<\/tr>\n
opstelten w<\/td>1.4142135623731<\/td>\n<\/tr>\n
schwarz tf<\/td>1.4142135623731<\/td>\n<\/tr>\n
medline plus<\/td>1.4142135623731<\/td>\n<\/tr>\n
loose-fitting clothing<\/td>1.4142135623731<\/td>\n<\/tr>\n
boardman kd<\/td>1.4142135623731<\/td>\n<\/tr>\n
beutner kr<\/td>1.4142135623731<\/td>\n<\/tr>\n
sawyer mh<\/td>1.4142135623731<\/td>\n<\/tr>\n
mandal bk<\/td>1.4142135623731<\/td>\n<\/tr>\n
chaves ss<\/td>1.4142135623731<\/td>\n<\/tr>\n
shanabrook bv<\/td>1.4142135623731<\/td>\n<\/tr>\n
likelihood of adherence<\/td>1.4142135623731<\/td>\n<\/tr>\n
mri scans<\/td>1.4142135623731<\/td>\n<\/tr>\n
simberkoff ms<\/td>1.4142135623731<\/td>\n<\/tr>\n
60-year period<\/td>1.4142135623731<\/td>\n<\/tr>\n
wu yn<\/td>1.4142135623731<\/td>\n<\/tr>\n
hill ha<\/td>1.4142135623731<\/td>\n<\/tr>\n
auditory canal<\/td>1.4142135623731<\/td>\n<\/tr>\n
multiple myeloma<\/td>1.4142135623731<\/td>\n<\/tr>\n
pregnant women<\/td>1.4142135623731<\/td>\n<\/tr>\n
out-of-pocket payments<\/td>1.4142135623731<\/td>\n<\/tr>\n
tool kit<\/td>1.4142135623731<\/td>\n<\/tr>\n
clinician look<\/td>1.4142135623731<\/td>\n<\/tr>\n
garner js<\/td>1.4142135623731<\/td>\n<\/tr>\n
north carolina<\/td>1.4142135623731<\/td>\n<\/tr>\n
murray av<\/td>1.4142135623731<\/td>\n<\/tr>\n
burden of illness<\/td>1.4142135623731<\/td>\n<\/tr>\n
mertz gj<\/td>1.4142135623731<\/td>\n<\/tr>\n
ready availability<\/td>1.4142135623731<\/td>\n<\/tr>\n
hearing impairments<\/td>1.4142135623731<\/td>\n<\/tr>\n
submitted work<\/td>1.4142135623731<\/td>\n<\/tr>\n
forbes hj<\/td>1.4142135623731<\/td>\n<\/tr>\n
temporal increase<\/td>1.4142135623731<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"parent":2257,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"class_list":["post-2475","page","type-page","status-publish","hentry"],"aioseo_notices":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/P9nUTT-DV","jetpack_likes_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/comments?post=2475"}],"version-history":[{"count":1,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2475\/revisions"}],"predecessor-version":[{"id":2476,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2475\/revisions\/2476"}],"up":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/pages\/2257"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/~ACP\/wp-json\/wp\/v2\/media?parent=2475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}